Eleazar Sukenik

Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Retrieved on: 
Wednesday, January 25, 2023
Psychoactive drug, Annual general meeting, Obesity, Hebrew University of Jerusalem, FSE, Hebrew language, Metabolic syndrome, CWY, Drug development, Therapy, MEAI, Eleazar Sukenik, CSE, Associate, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest results at Isranalytica 2023.

Key Points: 
  • The presentation, titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications," included data from recently announced pre-clinical results demonstrating efficacy of Clearmind’s drug candidate MEAI for treating obesity and metabolic syndrome.
  • Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, ranks as one of the world’s largest annual analytical chemistry conferences.
  • Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and Metabolism Laboratory, and he is an Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.
  • Along with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as part of Clearmind’s robust collaboration with the Hebrew University and its technology transfer company Yissum .

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Retrieved on: 
Thursday, January 19, 2023
CWY, Eleazar Sukenik, CSE, FSE, Safety, Hebrew University of Jerusalem, Therapy, Patient, Patent, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of two R&D projects with leading scientists from multiple disciplines at the Hebrew University as part of a collaboration established with the university’s technology transfer company, Yissum.

Key Points: 
  • The work included alterations of different regions of known molecules, to potentially improve their binding capabilities to the 5HT2A receptor.
  • The final stage of this project utilized an animal model to assess a possible increase in safety and efficacy.
  • These results are proof of the fruitful collaboration between Clearmind and leading academic institutions, which we value and appreciate," said Clearmind's CEO, Dr. Adi Zuloff-Shani.
  • These projects yielded several promising drug candidates that Clearmind and Yissum are now advancing into novel patent applications.

Equitybee Appoints Yaeli Gila as Vice President of Finance

Retrieved on: 
Tuesday, January 17, 2023
Professional Services, Technology, Software, Finance, Asset Management, Fintech, Banking, CPA, Weizmann Institute of Science, HR, BYU College of Physical and Mathematical Sciences, Accounting, Eleazar Sukenik, Mathematics, Hebrew University of Jerusalem, Knowledge, Fieldin Culbreth, Alvarion, KPMG, Arthur Andersen, Acquisition, AOL, Management, Physics

Equitybee , the startup employees' stock options funding solution, today announced the appointment of Yaeli Gila as vice president of finance.

Key Points: 
  • Equitybee , the startup employees' stock options funding solution, today announced the appointment of Yaeli Gila as vice president of finance.
  • Prior to joining Equitybee, Gila was the VP of finance for the global agtech start-up, Fieldin, Inc.
  • Before Fieldin, Gila was the VP of finance in the leading adtech platform Adap.tv.
  • “I am so thrilled to join Equitybee at such an exciting moment in our company’s history,” said Gila.

SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023
TEL, Central nervous system, MEAI, Human, Microdeletion syndrome, Overweight, Triglyceride, FSE, Animal, Palmitoylethanolamide, CSE, World Health Organization, CWY, Weight loss, Hebrew University of Jerusalem, Obesity, Eleazar Sukenik, Motivation, Liver, Pharmaceutical industry, Dietary supplement

TEL AVIV, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced initial positive pre-clinical results for treatment for obesity and the potential treatment of metabolic syndromes using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY).

Key Points: 
  • "We believe that this virtually untapped multibillion-dollar market creates significant opportunities for our joined collaboration with Clearmind by developing a unique drug candidate for the market to treat obesity."
  • Thus, this treatment may be beneficial for the treatment of compulsive-reward-seeking behavior or excessive consumption of sweet foods.
  • Mr. Oz Adler, the Chief Executive Officer and Chief Financial Officer of the Company, is a director of Clearmind.
  • Mr. Amitai Weiss is the Chairman of the board of directors of both Clearmind and the Company.

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023
Death, Liver disease, Associate, MEAI, Morgan Stanley, Metabolism, Human, Research, Hebrew language, Triglyceride, Overweight, FSE, LSD, Risk, Stanley, Animal, Drug development, CSE, Fatty liver disease, World Health Organization, Psilocybin, Novo Nordisk, CWY, Weight loss, Metabolic syndrome, Therapy, Hebrew University of Jerusalem, Obesity, Eleazar Sukenik, Motivation, Lilly, Liver, Dietary supplement, Pharmaceutical industry, Yissum Research Development Company of the Hebrew University, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.

Key Points: 
  • It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
  • Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver.
  • Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
  • This underserved multibillion-dollar market creates significant opportunities for Clearmind to generate substantial revenues, should MEAI reach the market as an obesity treatment.

Zohar Tadmor-Eilat Joins Cellebrite as Chief People Officer

Retrieved on: 
Monday, January 2, 2023
Zohar, CyberArk, Human resources, DI, CPO, Human, Bit-Tech, Culture, Hebrew University of Jerusalem, Eleazar Sukenik, Digital intelligence, HR, Management, Cellebrite, Tel Aviv University

Zohar will report to Yossi Carmil, Chief Executive Officer of Cellebrite, and will be a member of the Company’s executive management team.

Key Points: 
  • Zohar will report to Yossi Carmil, Chief Executive Officer of Cellebrite, and will be a member of the Company’s executive management team.
  • She succeeds Osnat Tirosh, who is leaving Cellebrite after ten years to pursue other career and professional growth opportunities.
  • As CPO, Zohar will be responsible for leading Cellebrite’s human resources (HR) and people functions, including executive recruitment, talent management, organizational and leadership development.
  • “Maintaining an engaged, ethical and innovative culture is critical to Cellebrite’s ability to attract and retain the best talent,” said Yossi Carmil, Chief Executive Officer of Cellebrite.

Revium Recovery, Inc. Announces Letter of Intent to Acquire LipoVac Ltd.

Retrieved on: 
Tuesday, December 20, 2022
OTC Markets Group, NLP, Research, Yissum Research Development Company of the Hebrew University, Security (finance), An Act to exempt a particular class of securities from the Securities and Exchange Act, Growth, Eleazar Sukenik, Hebrew University of Jerusalem, Sale, Lipovac

New York, NY, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Revium Recovery, Inc. (OTC Pink: RVRC) or ("RVRC) has entered into a non-binding letter of intent to acquire LipoVac, Ltd. ("LipoVac"), a privately held company.

Key Points: 
  • New York, NY, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Revium Recovery, Inc. (OTC Pink: RVRC) or ("RVRC) has entered into a non-binding letter of intent to acquire LipoVac, Ltd. ("LipoVac"), a privately held company.
  • A condition to closing is that Revium will complete a private placement of its securities with net proceeds to Revium of at least $7 million.
  • The combined Company anticipates executing on its strategy involving significant growth in shareholder value as the projects will be developed.
  • Neither RVRC nor LipoVac are subject to the reporting requirements of the Securities and Exchange Commission under the Securities and Exchange Act of 1934 as amended.

Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines

Retrieved on: 
Tuesday, January 3, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Transfer, Synthetic biology, GMP, Bio, Biotechnology, Weizmann Institute of Science, Doctor of Philosophy, Head, Assistant, Research, Hebrew language, Eleazar Sukenik, CRISPR, Gene expression, Lior, Biology, Synthetic, Hebrew University of Jerusalem, Biophysics, RNA, SPECS, Massachusetts Institute of Technology, Vaccine

Abintus Bio, Inc. (Abintus), a biotechnology company pioneering first-in-class, in vivo genetic medicines that engineer cells directly inside the body, today announced that Lior Nissim, Ph.D. , has joined the company as Head of Synthetic Biology.

Key Points: 
  • Abintus Bio, Inc. (Abintus), a biotechnology company pioneering first-in-class, in vivo genetic medicines that engineer cells directly inside the body, today announced that Lior Nissim, Ph.D. , has joined the company as Head of Synthetic Biology.
  • In this role, Dr. Nissim will be responsible for leading Abintus’ synthetic biology program to enable the advancement of products with tunable, cell-type specific therapeutic gene expression.
  • In connection with Dr. Nissim’s appointment and for his innovative synthetic biology platforms, Abintus has entered a research and option agreement with The Hebrew University’s Tech Transfer Company, Yissum .
  • “Adding next-generation synthetic biology capabilities to Abintus’ clinically proven gene delivery technology and commercial scale manufacturing process completes the critical requirements to enable successful development of in vivo genetic medicines that require cell-selective gene expression.

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

Retrieved on: 
Thursday, December 15, 2022
PEA, Acquisition, Canadian Securities Exchange, MEAI, Depression, Gonda, Clinical trial, Pharmacology, Research, Outline, Mental health, FDA, Hebrew University of Jerusalem, Cocaine, AUD, Science, FSE, Bar-Ilan University, Central nervous system, University, Frankfurt Stock Exchange, CWY, IPO, CSE, Eleazar Sukenik, IP, Obesity, Patent, Development, Patient, Therapy, Pharmaceutical industry, Management, BIRAD

Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani.
  • We believe our proprietary CMND-100, 5-methoxy-2-aminoindane (“MEAI”)- based treatment can help provide relief to millions around the world.
  • I joined Clearmind when the company was founded, after a thorough examination of the science and the psychedelic fields.
  • CEO of Clearmind Medicine Inc.
    Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Retrieved on: 
Wednesday, December 14, 2022
Physician, Person, Food, Fatty liver disease, Regulation of tobacco by the U.S. Food and Drug Administration, Calendar, TEL, Letter, EMA, Staff, Patient, NASH, Annual report, Research, The Annual Report, Hebrew University of Jerusalem, FDA, Writing, COVID-19, Clinical trial, Failure, Risk, Eleazar Sukenik, Marketing, Liver disease, Pharmaceutical industry

Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on the development of Aramchol.

Key Points: 
  • Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on the development of Aramchol.
  • Historically, Galmed has focused almost exclusively on developing Aramchol for the treatment of liver disease.
  • Galmed is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.
  • In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing.